Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. 더 보기
FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American:...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.025 | -2.63157894737 | 0.95 | 0.95 | 0.7511 | 4266 | 0.89634318 | CS |
4 | 0.165 | 21.7105263158 | 0.76 | 0.95 | 0.6571 | 12168 | 0.84341319 | CS |
12 | -0.436 | -32.0352681852 | 1.361 | 1.75 | 0.585 | 27534 | 1.07849083 | CS |
26 | -2.575 | -73.5714285714 | 3.5 | 3.68 | 0.585 | 24228 | 1.6205437 | CS |
52 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
156 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
260 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
기호 | 가격 | 볼륨 |
---|---|---|
VHAIVocodia Holdings Corp | US$ 0.0269 (-15.94%) | 34.59M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27.08 (-1.28%) | 30.9M |
XLFFinancial Select Sector | US$ 44.215 (-1.64%) | 19.06M |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 29.40 (1.48%) | 16.41M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 7.815 (0.19%) | 14.61M |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관